FDA grants Avastin hearing 6/28-29/2011

Genentech, the subsidiary of Roche, the pharmaceutical company that markets Avastin®, has requested, and been granted, a hearing in front of the Food and Drug Administration (FDA). The hearing will be held June 28-29, 2011, by the Oncologic Drugs Advisory Committee

The FDA’s Oncologic Drugs Advisory Committee last November voted 12 to 1 to rescind the approval for Avastin as a treatment for breast cancer, citing the risks outweighed the benefits.  Since then, the breast cancer community has reacted strongly and vocally. Day one of the hearing will be Genentech’s presentations to the committee, and day two will be the committee’s recommendations. Dr. Margaret Hamburg, the FDA commissioner, will make the final decision.

Genentech’s presentations will include input from the public. As I learn more information, I will update this post. Stay tuned.

5 6 7 8
© 2004-2011 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s